A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) Treatment Administered Once Daily on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Elafibranor (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Genfit
Most Recent Events
- 27 Aug 2020 Status changed from suspended to discontinued.
- 31 Mar 2020 Status changed from recruiting to suspended according to a Genfit media release.
- 31 Mar 2020 According to a Genfit media release, enrolment in this study have been paused due to Covid-19 pandemic.